{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:33:43Z","timestamp":1787762023329,"version":"build-2784847793"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>We assessed the efficacy and safety of sunitinib as the first-line treatment in metastatic renal cell carcinoma (mRCC) patients. The predictors of survival and efficacy in mRCC as identified from previous studies, including the Memorial Sloan Kettering Cancer Center (MSKCC) and the International Metastatic RCC Database Consortium (IMDC) factors, were also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Data from 56 patients with mRCC, treated with sunitinib at our institute (2006\u20132014), were analyzed retrospectively. Prognostic factors for overall survival (OS) and progression-free survival (PFS) were evaluated using univariate and multivariate analyses performed by log-rank test and Cox regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Fifty-one (91.1%) patients received starting dose of sunitinib of 50 mg\/day in 4\/2 schedule. The median PFS was 12.7 months (95% confidence interval [CI], 4.5\u201320.9 months) and the median OS was 16.9 months (95% CI, 3.8\u201329.9 months). The objective response rate was 27.5%. Dose interruption and reduction due to toxicities were required in 37.5% and 60.7% of patients, respectively. The most common Grades 3\u20134 toxicities were hand-foot syndrome (HFS) (23.2%), thrombocytopenia (16.1%), and hypertension (14.3%). The Eastern Cooperative Oncology Group performance status \u22652, hemoglobin &lt; lower limit of normal, neutrophil &gt; upper limit of normal (ULN), platelet &gt; ULN, no prior nephrectomy, metastatic sites &gt;1, liver metastases, lymph node metastases, and development of HFS were independent prognostic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Sunitinib treatment has acceptable efficacy and safety profile in Malaysian mRCC patients. The MSKCC and IMDC factors are relevant for predicting survival in our patient cohort while HFS is a promising prognostic predictor which warrants further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0973-1482.189247","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T09:03:38Z","timestamp":1531991018000},"page":"1303-1311","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma: A single center experience"],"prefix":"10.4103","volume":"14","author":[{"given":"Nahjatul Kursyiah","family":"Abd Ghafar","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology, University Malaya Medical Centre, Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adlinda","family":"Alip","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, University Malaya Medical Centre, Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng Aik","family":"Ong","sequence":"additional","affiliation":[{"name":"Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning Yi","family":"Yap","sequence":"additional","affiliation":[{"name":"Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marniza","family":"Saad","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, University Malaya Medical Centre, Kuala Lumpur, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,11,28]]},"reference":[{"key":"R1-20260109","doi-asserted-by":"crossref","first-page":"7497","DOI":"10.7314\/APJCP.2013.14.12.7497","article-title":"Clinical prognostic factors and survival outcome in renal cell carcinoma patients \u2013 A malaysian single centre perspective","volume":"14","author":"Yap","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11864-003-0039-2","article-title":"Metastatic renal cell carcinoma","volume":"4","author":"Flanigan","year":"2003","journal-title":"Curr Treat Options Oncol"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/107327481302000310","article-title":"Targeted therapy of kidney cancer: Keeping the art around the algorithms","volume":"20","author":"Fishman","year":"2013","journal-title":"Cancer Control"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N Engl J Med"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/bjc.2015.368","article-title":"Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients","volume":"113","author":"Donskov","year":"2015","journal-title":"Br J Cancer"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"555","DOI":"10.5301\/tj.5000342","article-title":"Co-occurring adverse events enable early prediction of progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib: A hypothesis-generating study","volume":"101","author":"Kucharz","year":"2015","journal-title":"Tumori"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1093\/annonc\/mdt288","article-title":"Clinical biomarkers of response in advanced renal cell carcinoma","volume":"24","author":"Ravaud","year":"2013","journal-title":"Ann Oncol"},{"key":"R10-20260109","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/bjc.2015.196","article-title":"Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma","volume":"113","author":"Gore","year":"2015","journal-title":"Br J Cancer"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1743-7563.2012.01525.x","article-title":"Management of sunitinib adverse events in renal cell carcinoma patients: The Asian experience","volume":"8","author":"Zhou","year":"2012","journal-title":"Asia Pac J Clin Oncol"},{"key":"R13-20260109","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1007\/s12032-014-0978-4","article-title":"Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: Experience in real-world clinical practice in Japan","volume":"31","author":"Miyake","year":"2014","journal-title":"Med Oncol"},{"key":"R14-20260109","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/jjco\/hyq146","article-title":"Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma","volume":"40","author":"Tomita","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"R15-20260109","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1159\/000330361","article-title":"Sunitinib for Asian patients with advanced renal cell carcinoma: A comparable efficacy with different toxicity profiles","volume":"80","author":"Kim","year":"2011","journal-title":"Oncology"},{"key":"R16-20260109","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4143\/crt.2009.41.2.67","article-title":"Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: A single cancer center experience in Korea","volume":"41","author":"Hong","year":"2009","journal-title":"Cancer Res Treat"},{"key":"R17-20260109","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ajco.12163","article-title":"Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy","volume":"10","author":"Lee","year":"2014","journal-title":"Asia Pac J Clin Oncol"},{"key":"R18-20260109","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.clgc.2014.11.004","article-title":"Efficacy and safety of an attenuated-dose sunitinib regimen in metastatic renal cell carcinoma: Results from a prospective registry in Singapore","volume":"13","author":"Tan","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"R19-20260109","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3760\/cma.j.issn.0366-6999.20132411","article-title":"Efficacy of sunitinib in patients with metastatic renal cell carcinoma: Initial experience in two Chinese centers","volume":"127","author":"He","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"R20-20260109","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.clgc.2014.03.012","article-title":"Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: A European multiinstitutional study","volume":"12","author":"Bamias","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"R21-20260109","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"R22-20260109","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1200\/JCO.2005.05.179","article-title":"Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma","volume":"23","author":"Mekhail","year":"2005","journal-title":"J Clin Oncol"},{"key":"R23-20260109","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.eururo.2014.11.054","article-title":"Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies","volume":"68","author":"Kroeger","year":"2015","journal-title":"Eur Urol"},{"key":"R24-20260109","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.eururo.2011.09.003","article-title":"Lymph node dissection in renal cell carcinoma","volume":"60","author":"Capitanio","year":"2011","journal-title":"Eur Urol"},{"key":"R25-20260109","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/jjco\/hyv045","article-title":"Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: Efficacy, safety and biomarker analyses in 1689 consecutive patients","volume":"45","author":"Akaza","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"R26-20260109","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1093\/annonc\/mds145","article-title":"Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: A national registry-based study","volume":"23","author":"Poprach","year":"2012","journal-title":"Ann Oncol"},{"issue":"31 Suppl","key":"R27-20260109","doi-asserted-by":"crossref","first-page":"e15622","DOI":"10.1200\/jco.2013.31.15_suppl.e15622","article-title":"Hand-foot syndrome (HFS) and asthenia\/fatigue (A\/F) as biomarkers of sunitinib efficacy in Chinese patients (pts) with metastatic renal cell carcinoma (mRCC)","author":"Qin","year":"2013","journal-title":"J Clin Oncol"},{"key":"R28-20260109","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2009.26.5561","article-title":"Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206","volume":"28","author":"Rini","year":"2010","journal-title":"J Clin Oncol"},{"key":"R29-20260109","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","article-title":"Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial","volume":"14","author":"Motzer","year":"2013","journal-title":"Lancet Oncol"},{"key":"R30-20260109","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S1470-2045(13)70465-0","article-title":"Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: A randomised open-label phase 3 trial","volume":"14","author":"Hutson","year":"2013","journal-title":"Lancet Oncol"},{"key":"R31-20260109","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.urolonc.2010.07.015","article-title":"The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: A prospective single-center study","volume":"30","author":"Baldazzi","year":"2012","journal-title":"Urol Oncol"},{"key":"R32-20260109","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000337079","article-title":"Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma?","volume":"58","author":"Sella","year":"2012","journal-title":"Chemotherapy"},{"key":"R33-20260109","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/annonc\/mdr275","article-title":"Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma","volume":"23","author":"Sabatier","year":"2012","journal-title":"Ann Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363817-201814060-00025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:11:49Z","timestamp":1787760709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363817-201814060-00025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.4103\/0973-1482.189247","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}